TRANSCEND-T2D-1
retatrutide monotherapy lowers HbA1c by up to 1.1 percentage points more than placebo and body weight by up to 15 percent
Phase 3, double-blind trial in 537 adults with type 2 diabetes inadequately controlled on diet and exercise (mean HbA1c 7.9 percent, BMI 35.8, diabetes duration 2.5 years), randomised to once-weekly retatrutide 4, 9 or 12 mg or placebo for 40 weeks at 48 sites in the USA, Mexico and India. HbA1c fell by 1.69, 1.86 and 1.94 percentage points versus 0.81 with placebo (treatment differences -0.88 to -1.12, all p below 0.0001); body weight fell by 11.5, 13.9 and 15.3 percent versus 2.6 percent. Adverse events were mainly mild to moderate gastrointestinal; discontinuation for adverse events 2 to 5 percent; no severe hypoglycaemia. Published in The Lancet and discussed in the EASD 2026 oral session 'GLP-1 and friends' in Milan. No cardiovascular outcome data yet.
Join us
Join the Global Primary Care Cardio Network. Membership is free.
Would you like to tell us more about yourself?
Interests
We will send you an email with a link to confirm your registration.
